Related Experiment Video
Updated: Jan 27, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Dephosphorylation-induced EZH2 activation mediated RECK downregulation by ERK1/2 signaling
1Department of Clinical Nutrition, Jinhua Municipal Central Hospital, Jinhua, China.
Abstract:
The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene, a widely known cancer inhibitor, could effectively suppress cancer metastasis and angiogenesis. Downregulation or loss of RECK expression frequently occurs during cancer progression. However, the mechanism underlying RECK dysregulation has not been fully elucidated. Herein, we reported for the first time that enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, could epigenetically attenuate RECK expression via catalyzing H3K27 trimethylation (H3K27me3) within the RECK promoter. Furthermore, we also proved, for the first time, the involvement of EZH2 in the inhibition of RECK by extracellular signal-related kinases (ERK)-1/2 signaling. Next, we revealed that the modulation of the enzymic activity of EZH2 resulting from posttranslational phosphorylation at the serine-21 site was responsible for the increased enrichment of H3K27me3 at the RECK promoter region by ERK1/2 signaling. Collectively, the results of our study shed more light on the mechanisms responsible for the dysregulation of RECK by the ERK1/2 pathway.
Insights
The enhancer of zeste homolog 2 (EZH2) enzyme epigenetically silences the RECK gene, a cancer inhibitor, by promoting H3K27 trimethylation. Extracellular signal-related kinases (ERK)-1/2 signaling further enhances this silencing mechanism.
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Research
Background:
- The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene inhibits cancer metastasis and angiogenesis.
- RECK expression is often downregulated in progressing cancers, but the underlying mechanisms remain unclear.
Purpose of the Study:
- To elucidate the epigenetic mechanisms regulating RECK expression.
- To investigate the role of enhancer of zeste homolog 2 (EZH2) and extracellular signal-related kinases (ERK)-1/2 signaling in RECK dysregulation.
Main Methods:
- Chromatin immunoprecipitation assays to assess H3K27 trimethylation at the RECK promoter.
- Western blotting to detect protein levels and phosphorylation.
- In vitro assays to determine EZH2 activity modulation.
Main Results:
- EZH2 directly attenuates RECK expression by catalyzing H3K27 trimethylation on the RECK promoter.
- ERK1/2 signaling enhances EZH2 activity, leading to increased H3K27 trimethylation and RECK suppression.
- Posttranslational phosphorylation of EZH2 at serine-21 by ERK1/2 is crucial for this regulatory process.
Conclusions:
- EZH2 epigenetically represses RECK expression via H3K27 trimethylation.
- The ERK1/2 pathway modulates EZH2 activity, contributing to RECK downregulation in cancer progression.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Receptor-mediated Endocytosis
Paracrine Signaling
Endocrine Signaling
What is Cell Signaling?
Bacterial Signaling

